NCT00440479View on ClinicalTrials.gov

ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Multiple MyelomaHematological Neoplasms

Interventions

DRUG

Bortezomib

dose as determined (observational study) by treating physician

Trial Locations (9)

Unknown

Bergen op Zoom

Breda

Ede Gld

Flushing

Nijmegen

Rotterdam

Terneuzen

Tilburg

Utrecht

All Listed Sponsors

lead

Janssen-Cilag B.V.

INDUSTRY

NCT00440479 - ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. | Biotech Hunter | Biotech Hunter